Abstract
In vitro anti-tubercular activity of a series of 15 novel 2,3-dihydroquinazolin-4(1H)-one analogues were evaluated against Mycobacterium tuberculosis H37Ra (ATCC 25177 strain). Among the series, seven compounds showed moderate to good anti-TB activity with minimum inhibitory concentration (MIC) values ranging from 25.0–12.5 μg/mL. Further, in silico experiments were carried out to identify the probable ligand-protein interaction. Molecular docking of the target compounds into the active site of enzymes 1DQY Antigen 85C from Mycobacterium Tuberculosis and 2NSD Enoyl Acyl Carrier Protein Reductase reveals notable information on the possible binding interactions.
Similar content being viewed by others
References
Sotgiu G, Centis R, D’ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015;5:a017822–a017822.
Singh P, Mishra AK, Malonia SK, Chauhan DS, Sharma VD, Venkatesan K, Katoch VM. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. J Commun Dis. 2006;38:288–98.
Srivastava S, Srivastava S. Biological activity of quinazoline: A review. Int J Pharm Sci. 2015;6:1206–13.
Mhaske SB, Argade NP. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. Tetrahedron. 2006;62:9787–826.
Mehta DR, Naravane JS, Desai RM. Vasicinone. A bronchodilator principle from Adhatoda Vasica Nees (N. O. Acanthaceae.). J. Org. Chem.1963;28:445–8.
Amin AH, Mehta DR. A bronchodilator alkaloid (vasicinone) from Adhatoda vasica Nees. Nature. 1959;183:1317–1317.
Joshi BS, Newton MG, Lee DW, Barber AD, Pelletier SW. Reversal of absolute stereochemistry of the pyrrolo[2,1-b]quinazoline alkaloids vasicine, vasicinone, vasicinol and vasicinolone. Tetrahedron Asymmetry. 1996;7:25–8.
Atal, C. K. Chemistry and pharmacology of vasicine: a new oxytocic and abortifacient. Delhi: Raj Bandu Industrial Co; 1980.
Ghosal S, Chauhan PSRB, Mehta R. Alkaloids of Sida cordifolia. Phytochemistry. 1975;14:830–2.
Al-Shamma A, Drake S, Flynn DL, Mitscher LA, Park YH, Rao GSR, Simpson A, Swayze JK, Veysoglu T, Wu SS. Antimicrobial agents from higher plants. Antimicrobial agents from Peganum harmala seeds. J Nat Prod. 1981;44:745–7.
Kamal A, Ramana KV, Rao MV. Chemoenzymatic synthesis of pyrrolo[2,1-b]quinazolinones: lipase-catalyzed resolution of vasicinone. J Org Chem. 2001;66:997–1001.
Molina P, Tarraga A, Gonzalez-Tejero A. A convenient divergent approach to the alkaloids isaindigotone and luotonin A. Synthesis. 2000;11:1523–5.
Zhang H, Liu H, Luo X, Wang Y, Liu Y, Jin H, Liu Z, Yang W, Yu P, Zhang L, Zhang L. Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors. Eur J Med Chem. 2018;152:235–52.
Nagaladinne N, Hindustan A, Nayakanti D. Synthesis, characterization and docking studies of N-methyl-2, 3-Dihydro quinazolin-4-ones linked 1,3-thiazole hybrids as potent anti-tubercular agents. Indian J Pharm Sci. 2020;82:984.
Marvania B, Lee PC, Chaniyara R, Dong H, Suman S, Kakadiya R, Su TL. Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. Bioorg Med Chem. 2011;19:1987–98.
El-Azab AS, ElTahir KE. Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities. Bioorg Med Chem Lett. 2012;22:1879–85.
Maurya HK, Verma R, Alam S, Pandey S, Pathak V, Sharma S, Gupta A. Studies on substituted benzo[h]quinazolines, benzo[g]indazoles, pyrazoles, 2,6-diarylpyridines as anti-tubercular agents. Bioorg Med Chem Lett. 2013;23:5844–9.
Dukat M, Alix K, Worsham J, Khatri S, Schulte MK. 2-Amino-6-chloro-3,4-dihydroquinazoline: a novel 5-HT3 receptor antagonist with antidepressant character. Bioorg Med Chem Lett. 2013;23:5945–8.
Akester JN, Njaria P, Nchinda A, Le Manach C, Myrick A, Singh V, Lawrence N, Njoroge M, Taylor D, Moosa A, Smith AJ. Synthesis, structure–activity relationship, and mechanistic studies of aminoquinazolinones displaying antimycobacterial activity. ACS Infect Dis. 2020;6:1951–64.
Jafari E, Khajouei MR, Hassanzadeh F, Hakimelahi GH, Khodarahmi GA. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities. Res Pharm Sci. 2016;11:1–14.
Couturier C, Lai C, Pellet A, Upton A, Kaneko T, Perron C, Cogo E, Menegotto J, Bauer A, Scheiper B, Lagrange S, Bacque E. Identification and optimization of a new series of anti-tubercular quinazolinones. Bioorg Med Chem Lett. 2016;26:5290–9.
Maddali NK, Viswanath IK, Murthy YLN, Bera R, Takhi M, Rao NS, Gudla V. Design, synthesis and molecular docking studies of quinazolin-4-ones linked to 1,2,3-triazol hybrids as Mycobacterium tuberculosis H37Rv inhibitors besides antimicrobial activity. Med Chem Res. 2019;28:559–70.
Dutta A, Trivedi P, Kulashetra A, Kumar A, Chaturvedi V, Sarma D. Sustainable parts‐per‐million level catalysis with FeIII: one‐pot cascade synthesis of 2,3‐dihydroquinazolin‐4(1H)‐ones in water. Appl Organomet Chem. 2021;35:e6116.
Balaraman K, Kesavan V. Efficient copper(II) acetate catalyzed homo- and heterocoupling of terminal alkynes at ambient conditions. Synthesis. 2010;20:3461–6.
McClachy JK. Susceptibility testing of mycobacteria. Lab Med. 1978;9:47–52.
Acknowledgements
DS is thankful to Department of Biotechnology, Ministry of Science and Technology, New Delhi, India for a research grant (BT/PR24684/NER/95/810/2017). AD thanks DBT, New Delhi for Research Fellowship. The financial assistance of UGC-SAP programme to the Department of Chemistry, Dibrugarh University is also gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Dutta, A., Trivedi, P., Gogoi, D. et al. Anti-TB evaluation of novel 2,3-dihydroquinazolin-4(1H)-ones and in silico studies of the active compounds. Med Chem Res 30, 1366–1376 (2021). https://doi.org/10.1007/s00044-021-02733-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-021-02733-6